Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Market Outline:
The 9MM Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
NmCRPC stands for Non-metastatic Castration-Resistant Prostate Cancer. It is a subtype of prostate cancer that has become resistant to hormone therapy (also known as androgen deprivation therapy or ADT) but has not yet spread to other parts of the body, as confirmed by imaging tests such as bone scans and CT scans. While NmCRPC does not show detectable metastases on imaging tests, it carries a significant risk of developing metastatic disease over time. The risk of metastasis varies depending on factors such as PSA doubling time, Gleason score, and other clinical characteristics. NmCRPC represents an intermediate stage in the progression of prostate cancer, where the cancer becomes resistant to hormone therapy but has not yet spread to distant sites. Close monitoring, timely intervention, and access to emerging therapies through clinical trials are crucial for improving outcomes and quality of life for patients with NmCRPC.
Report has covered granular-level analysis in each mapped market
Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC), Disease Burden Analysis:
In United States the incidence of nmCRPC is about 50,000–60,000 cases per year
As per studies meta-analysis the estimated prevalence range between 2.1%-8.3% in different countries
Treatment Landscape:
Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) market is struggling to get an effective treatment
The development of therapeutic strategies for the treatment of nmCRPC is a challenging task due to the lack of radiologic evidence of metastatic disease and the absence of clinical symptoms
The developement of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each drug type:
Report has examined the how many and what type of cases refer to which type of therapy based on experts opinion analysis.
Untreated Prevalent Pool of Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)
Conducive reimbursement, pricing strategies, and market access ecosystems
Huge medical unmet need
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Lack of timely diagnosis
Research gap
Treatment compliance and adherence
Recent Developments:
Aug, 2023: XTANDI received Priority Review from FDA in the treatment of Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
5-Europe Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
Janssen Biotech, Inc.
Sun Pharma, Inc.
Astellas Pharma, Inc.
Bayer
Pfizer
Sanofi Genzyme
Bristol Myers Squibb
Clovis Oncology
Merck
Others
Reason to buy this report:
Fostering Understanding on Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Drug Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
